Literature DB >> 21935733

Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Andrea Salonia1, Andrea Gallina, Firas Abdollah, Alberto Briganti, Umberto Capitanio, Nazareno Suardi, Matteo Ferrari, Marco Raber, Renzo Colombo, Massimo Freschi, Patrizio Rigatti, Francesco Montorsi.   

Abstract

PURPOSE: To examine the association between positive surgical margins (PSMs) and preoperative circulating estradiol (E(2)), total testosterone (tT), and sex hormone-binding globulin (SHBG) in patients undergoing retropubic radical prostatectomy (RRP).
METHODS: A cohort of 665 non-screened patients who underwent RRP at a single institute was studied. Serum tT, E(2), and SHBG were measured the day before surgery (8-10 AM: ) in all cases. Logistic regression models tested the association between predictors [e.g., PSA, clinical stage, biopsy Gleason sum, body mass index (BMI), tT, E(2), and SHBG] and PSM. Circulating tT was included in the model as both a continuous variable and a categorized variable [according to the definition of hypogonadism (<3 ng/ml)].
RESULTS: PSMs were found in 175 patients (26.3%) within the whole cohort of men and in 78 (16.2%) of the pT2 patients. Patients with PSMs had significantly higher PSA, a higher proportion of more advanced clinical stage, and a lower rate of well-differentiated biopsy Gleason sum than those without PSMs (all P ≤ 0.03). Conversely, no significant differences were found regarding age, BMI, preoperative tT, E(2), and SHBG between patients with and without PSMs. At multivariate analysis, tT, hypogonadism, E(2), and SHBG were not significantly associated with PSMs, after accounting for routinely available preoperative parameters.
CONCLUSIONS: In contrast to previously published data, preoperative tT was not an independent predictive factor for PSM at RRP. Likewise, hypogonadism, E(2), and SHBG did not achieve independent predictor status for PSM, after accounting for routinely available preoperative parameters.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935733     DOI: 10.1007/s00345-011-0761-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study.

Authors:  Abdelouahid Tajar; Gianni Forti; Terence W O'Neill; David M Lee; Alan J Silman; Joseph D Finn; György Bartfai; Steven Boonen; Felipe F Casanueva; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Ilpo T Huhtaniemi; Frederick C W Wu
Journal:  J Clin Endocrinol Metab       Date:  2010-02-19       Impact factor: 5.958

2.  Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.

Authors:  Alberto Briganti; Felix K-H Chun; Georg C Hutterer; Andrea Gallina; Shahrokh F Shariat; Andrea Salonia; Vincenzo Scattoni; Luc Valiquette; Francesco Montorsi; Patrizio Rigatti; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2007-03-06       Impact factor: 20.096

3.  The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.

Authors:  Jiri Heracek; Michael Urban; Jana Sachova; Jitka Kuncova; Vaclav Eis; Vaclav Mandys; Richard Hampl; Luboslav Starka
Journal:  Neuro Endocrinol Lett       Date:  2007-02       Impact factor: 0.765

4.  Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures.

Authors:  Alexandre Paul; Guillaume Ploussard; Nathalie Nicolaiew; Evanguelos Xylinas; Norman Gillion; Alexandre de la Taille; Dimitri Vordos; Andras Hoznek; René Yiou; Claude Clément Abbou; Laurent Salomon
Journal:  Eur Urol       Date:  2009-09-17       Impact factor: 20.096

5.  Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?

Authors:  Alexandre E Pelzer; Daniela Colleselli; Jasmin Bektic; Georg Schaefer; Stefano Ongarello; Christian Schwentner; Leo Pallwein; Michael Mitterberger; Eberhard Steiner; Georg Bartsch; Wolfgang Horninger
Journal:  BJU Int       Date:  2008-03-13       Impact factor: 5.588

6.  American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.

Authors:  Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau
Journal:  Endocr Pract       Date:  2002 Nov-Dec       Impact factor: 3.443

7.  Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).

Authors:  Frank Giton; Alexandre de la Taille; Yves Allory; Hervé Galons; Francis Vacherot; Pascale Soyeux; Claude Clément Abbou; Sylvain Loric; Olivier Cussenot; Jean-Pierre Raynaud; Jean Fiet
Journal:  J Steroid Biochem Mol Biol       Date:  2008-02-08       Impact factor: 4.292

8.  Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.

Authors:  Sang Eun Lee; Jae Seung Chung; Byung Kyu Han; Chan Soo Park; Ki Hyuk Moon; Seok-Soo Byun; Gheeyoung Choe; Sung Kyu Hong
Journal:  Eur Urol       Date:  2008-03-07       Impact factor: 20.096

Review 9.  Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.

Authors:  Ofer Yossepowitch; Anders Bjartell; James A Eastham; Markus Graefen; Bertrand D Guillonneau; Pierre I Karakiewicz; Rodolfo Montironi; Franceso Montorsi
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096

Review 10.  The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.

Authors:  Helmut Bonkhoff; Richard Berges
Journal:  Eur Urol       Date:  2008-11-06       Impact factor: 20.096

View more
  1 in total

1.  Serum 17β-estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer.

Authors:  Thomas J Schnoeller; Julie Steinestel; Friedemann Zengerling; Andres J Schrader; Florian Jentzmik
Journal:  World J Urol       Date:  2015-04-24       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.